Energesis Pharmaceuticals

Energesis Pharmaceuticals is a Boston, Massachusetts-based biopharmaceutical company focused on developing oral obesity drugs that increase energy expenditure by restoring healthy brown fat levels. The company was founded by Dr. Brian Freeman, MD, and aims to create therapies that address obesity through energy expenditure rather than just appetite suppression. Their lead program, EGS-2632, is a proprietary oral combination candidate designed to safely increase brown fat-mediated energy expenditure and support high-quality weight loss solely from fat.

The company's lead program, EGS-2632, is a proprietary oral combination of two previously approved drugs being developed for obesity. This approach differs from most marketed obesity drugs by targeting energy expenditure instead of just reducing energy intake. Preclinical studies have shown that EGS-2632 exhibits synergistic efficacy when combined with marketed GLP-1 agents.

Energesis Pharmaceuticals is based in Boston, Massachusetts, and can be contacted via email at info@energesispharma.com. The company also maintains a presence on LinkedIn. For specific questions about their crowdfunding campaign, inquiries should be directed through the Q&A feature on their BioTech Funding Portal page.

The Trustburn page shows a rating of 4.2 out of 5 stars based on 11 reviews. The reviews are all from 2022 and 2023, with the most recent dated November 19, 2023. The rating split includes several 5-star reviews, multiple 4-star reviews, and two 3-star reviews.

Reviewers consistently praise Energesis Pharmaceuticals for the high quality and effectiveness of their products. Many customers highlight the excellent customer service and the user-friendly website that makes ordering easy. Some reviewers note that the company never disappoints and provides outstanding service compared to other brands they have tried.

Energesis Pharmaceuticals focuses on a differentiated approach to obesity treatment by targeting energy expenditure rather than just appetite suppression. Their strategy involves recruiting brown fat to create more of this energy-burning tissue, which helps regulate body weight. This method aims to achieve muscle-preserving weight loss without relying solely on appetite suppression mechanisms.

The company's mission is to develop a new class of drugs that gives people living with obesity better options and improves public health. Their vision is a future where obesity is treated like other complex diseases using combinations of medicines with distinct mechanisms. The goal is not just weight loss, but meaningful and sustainable patient benefit.

Energesis Pharmaceuticals is currently testing the waters for a Regulation Crowdfunding offering on the BioTech Funding Portal. This allows them to gauge interest before formally launching a securities offering. The company is preclinical stage, meaning their product candidates have not yet been approved by the FDA for the treatment of obesity or any other condition.

The company emphasizes that safety is paramount in their development process, drawing from lessons learned at their previous company, Zafgen. They use two drugs with long safety records at a fraction of their approved doses to minimize risk. Understanding the molecular targets of their candidates is also a key part of their scientific approach.

Energesis Pharmaceuticals uses adult human brown adipocyte stem/progenitor cells to discover compounds and targets that promote new brown fat formation. This human discovery platform allows them to specifically target the expenditure side of the weight maintenance equation. Their science platform focuses on creating more brown fat to help the body burn more calories.

The company was founded by accomplished scientists and an experienced obesity drug development entrepreneur with the goal of creating therapies that address obesity through energy expenditure. Dr. Freeman, MD, co-founded the company after lessons from his previous venture, Zafgen, which pioneered MetAP2 inhibitors for obesity. The team has advanced their science with nearly a dozen peer-reviewed grants.

Energesis Pharmaceuticals is building a pipeline of obesity therapeutics with a focus on energy metabolism. They are developing a new class of obesity drug candidates designed to safely increase the body's energy expenditure. The company is located in Boston, MA, and is actively seeking partnerships and media inquiries.

Energesis Pharmaceuticals is developing a new class of obesity drug candidates designed to safely increase the body's energy expenditure by restoring a healthy level of brown fat. Their approach seeks to increase energy expenditure, which is the first to specifically target the expenditure rather than the intake side of the weight maintenance equation. This novel approach aims to provide a differentiated treatment for obesity.

The official website of Energesis Pharmaceuticals is energesispharma.com.